Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium
Streptococcus pneumoniae causes a high disease burden including pneumonia, meningitis and septicemia. Both a polysaccharide vaccine targeting 23 serotypes (PPV23) and a 13-valent conjugate vaccine (PCV13) are indicated for persons aged over 50 years. We developed and parameterized a static multi-cohort model to estimate the incremental cost-effectiveness and budget-impact of these vaccines at different uptake levels. Using three different vaccine efficacy scenarios regarding non-invasive pneumococcal pneumonia and extensive uni- and multivariate sensitivity analyses, we found a strong preferen... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2018 |
Reihe/Periodikum: | Human Vaccines & Immunotherapeutics, Vol 14, Iss 5, Pp 1218-1229 (2018) |
Verlag/Hrsg.: |
Taylor & Francis Group
|
Schlagwörter: | pneumococcal / vaccine / adult / economic evaluation / cost-effectiveness / Immunologic diseases. Allergy / RC581-607 / Therapeutics. Pharmacology / RM1-950 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28563516 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1080/21645515.2018.1428507 |